Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Sep;60(3):389–393. doi: 10.1038/bjc.1989.291

Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications.

J B Sørensen 1, J H Badsberg 1, H H Hansen 1
PMCID: PMC2247192  PMID: 2789948

Abstract

The prognostic factors for response to chemotherapy and the prognostic impact of response status on survival, relative to other prognostic variables, were evaluated among 53 responding (9 complete responses; 44 partial responses) and 165 non-responding patients with inoperable adenocarcinoma of the lung (ACL). Multiple logistic regression analysis, including 27 pretreatment variables, revealed that the only significant predictor of response was bidimensionally measurable disease parameter (P = 0.02), followed by brain metastases that were negatively correlated to response, although insignificantly (P = 0.10). Univariate landmark analyses among patients alive at 8, 12, 16 and 24 weeks showed a trend towards better survival for responders compared with non-responders, but did not reach a significant level at any time (P values 0.78, 0.57, 0.23 and 0.12, respectively). Death hazard ratios for responders to non-responders were 0.91, 0.89, 0.79 and 0.73. Multivariate regression analysis among patients alive at 16 weeks demonstrated a significant impact on survival for performance status, non-radical tumour resection, liver metastases and LDH, while the impact of response status in comparison was weak and insignificant. This reflects the unsatisfactory treatment results achieved in inoperable ACL, with the majority of responses being partial, and calls for improvement of the cytostatic treatment currently available.

Full text

PDF
389

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aisner J., Hansen H. H. Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):979–986. [PubMed] [Google Scholar]
  2. Anderson J. R., Cain K. C., Gelber R. D. Analysis of survival by tumor response. J Clin Oncol. 1983 Nov;1(11):710–719. doi: 10.1200/JCO.1983.1.11.710. [DOI] [PubMed] [Google Scholar]
  3. Eagan R. T., Fleming T. R., Schoonover V. Evaluation of response criteria in advanced lung cancer. Cancer. 1979 Sep;44(3):1125–1128. doi: 10.1002/1097-0142(197909)44:3<1125::aid-cncr2820440348>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  4. Eagan R. T., Frytak S., Creagan E. T., Richardson R. L., Coles D. T., Jett J. R. Differing response rates and survival between squamous and non-squamous non-small cell lung cancer. Comparison of CAP versus MAP. Am J Clin Oncol. 1986 Jun;9(3):249–254. doi: 10.1097/00000421-198606000-00014. [DOI] [PubMed] [Google Scholar]
  5. O'Connell J. P., Kris M. G., Gralla R. J., Groshen S., Trust A., Fiore J. J., Kelsen D. P., Heelan R. T., Golbey R. B. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 1986 Nov;4(11):1604–1614. doi: 10.1200/JCO.1986.4.11.1604. [DOI] [PubMed] [Google Scholar]
  6. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Rapp E., Pater J. L., Willan A., Cormier Y., Murray N., Evans W. K., Hodson D. I., Clark D. A., Feld R., Arnold A. M. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. J Clin Oncol. 1988 Apr;6(4):633–641. doi: 10.1200/JCO.1988.6.4.633. [DOI] [PubMed] [Google Scholar]
  8. Ruckdeschel J. C., Finkelstein D. M., Mason B. A., Creech R. H. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens. J Clin Oncol. 1985 Jan;3(1):72–79. doi: 10.1200/JCO.1985.3.1.72. [DOI] [PubMed] [Google Scholar]
  9. Sørensen J. B., Clerici M., Hansen H. H. Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemother Pharmacol. 1988;21(2):89–102. doi: 10.1007/BF00257354. [DOI] [PubMed] [Google Scholar]
  10. Sørensen J. B., Hansen H. H. Combination chemotherapy for advanced adenocarcinoma of the lung. A review. Cancer Chemother Pharmacol. 1988;21(2):103–116. doi: 10.1007/BF00257355. [DOI] [PubMed] [Google Scholar]
  11. Sørensen J. B., Hansen H. H., Dombernowsky P., Bork E., Malmberg R., Aabo K., Bødker B., Hansen M. Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs. J Clin Oncol. 1987 Aug;5(8):1169–1177. doi: 10.1200/JCO.1987.5.8.1169. [DOI] [PubMed] [Google Scholar]
  12. Sørensen J. B., Hirsch F. R., Olsen J. The prognostic implication of histopathologic subtyping of pulmonary adenocarcinoma according to the classification of the World Health Organization. An analysis of 259 consecutive patients with advanced disease. Cancer. 1988 Jul 15;62(2):361–367. doi: 10.1002/1097-0142(19880715)62:2<361::aid-cncr2820620222>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  13. Warr D., McKinney S., Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol. 1984 Sep;2(9):1040–1046. doi: 10.1200/JCO.1984.2.9.1040. [DOI] [PubMed] [Google Scholar]
  14. Weiss G. B., Bunce H., 3rd, Hokanson J. A. Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. Control Clin Trials. 1983 Mar;4(1):43–52. doi: 10.1016/s0197-2456(83)80011-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES